These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8475503)

  • 1. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
    Kurihara N; Yanagisawa H; Jin Z; Wada O
    Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
    Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
    J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,1'-Ethylidenebis[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia-myalgia syndrome.
    Emslie-Smith AM; Mayeno AN; Nakano S; Gleich GJ; Engel AG
    Neurology; 1994 Dec; 44(12):2390-2. PubMed ID: 7991132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome.
    Suzuki S; Tourkina E; Ludwicka A; Hampton M; Bolster M; Maize J; Silver R
    Proc Assoc Am Physicians; 1996 Jul; 108(4):315-22. PubMed ID: 8863345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive deficits in a murine model of the eosinophilia-myalgia syndrome: a preliminary report.
    Middaugh LD; Nussbaum R; Ludwicka A; Bolster MB; Silver RM
    Neurotoxicol Teratol; 1996; 18(5):595-601. PubMed ID: 8888024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Cosgrove JW; Latham PS; Mayeno AN
    Toxicol Appl Pharmacol; 1994 May; 126(1):108-13. PubMed ID: 8184420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms.
    Brenneman DE; Page SW; Schultzberg M; Thomas FS; Zelazowski P; Burnet P; Avidor R; Sternberg EM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):1029-35. PubMed ID: 8355179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan.
    Simat TJ; Kleeberg KK; Müller B; Sierts A
    Adv Exp Med Biol; 1999; 467():469-80. PubMed ID: 10721090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
    Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
    J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
    Müller B; Pacholski C; Simat T; Steinhart H
    Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.
    Barth H; Klein R; Berg PA
    Clin Exp Immunol; 2001 Nov; 126(2):187-92. PubMed ID: 11703359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
    Varga J; Jimenez SA; Uitto J
    J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.
    Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S
    Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,1'-Ethylidenebis[L-tryptophan], a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome, suppresses mRNA expression of hypothalamic corticotropin-releasing hormone in Lewis (LEW/N) rat brain.
    Brady LS; Page SW; Thomas FS; Rader JL; Lynn AB; Misiewicz-Poltorak B; Zelazowski E; Crofford LJ; Zelazowski P; Smith C
    Neuroimmunomodulation; 1994 Jan; 1(1):59-65. PubMed ID: 8528886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.